Abaxis — Merger or Acquisition (May 2018)
16 slides from Abaxis's merger presentation, May 16, 2018
Slide 1: Introducing You to Zoetis
INTRODUCING YOU TO ZOETIS May 16, 2018
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS Statements included in this communication which are not historical in nature or do not relate to current facts are intended to be, and are hereby identified as, forward-looking statements for purposes of the safe harbor provided by Section 27A of the Securities Act of 1933
Slide 3: Important Additional Information
IMPORTANT ADDITIONAL INFORMATION In connection with the proposed transaction between Zoetis and Abaxis, Abaxis expects to file with the SEC a proxy statement of Abaxis, as well as other relevant documents concerning the proposed transaction. This communication is not a substitute for the proxy state
Slide 4: Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines
Building on more than 60 years of experience, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products, genetic tests, biodevices and a range of services.
Slide 5: Our Vision and Our Mission
OUR VISION OUR VISION GUIDES OUR ASPIRATIONS Our products, services and people will be the most valued by animal health customers around the world. OUR MISSION OUR MISSION GUIDES OUR ACTIONS We build on a six-decade history and singular focus on animal health to bring customers quality products, ser
Slide 6: Zoetis at a Glance
MANUFACTURING ANIMAL CORE SITES $ 25 8 SPECIES 5.3 APPROXIMATE APPROXIMATE COLLEAGUES R&D NUMBER OF BILLION 300 PRODUCT LINES ANNUAL REVENUE 1,000 WE PROVIDE VACCINES MEDICINES DIAGNOSTICS MAJOR PRODUCT GENETIC TESTS YEARS OF CATEGORIES BIODEVICES 5 SERVICES 60+ EXPERIENCE MARKET PRESENCE IN APPROXI
Slide 7: Addressing Customer Needs: The Zoetis Advantage
ADDRESSING CUSTOMER NEEDS THE ZOETIS ADVANTAGE • Global Leadership and Scale • Diverse Portfolio • Interconnected Capabilities: • Direct Customer Relationships • Innovation • High Quality Manufacturing • Singular Focus
Slide 8: Zoetis Leads Animal Health Industry
ZOETIS LEADS ANIMAL HEALTH INDUSTRY 2017 AH REPORTED SALES (INCLUDING NON-AH SALES1) 6,000 5.3Bn Since 2013, AH industry Mn) 5,000 has grown avg. of 5-6% — 4.4Bn with Zoetis growing in line 3.9Bn (US$ 4,000 with or faster than the sales 3.1Bn market — an average of 7% 3,000 5,307 for same period. 44
Slide 9: Innovating Across the Continuum of Care
INNOVATING ACROSS THE CONTINUUM OF CARE PREDICT PREVENT DETECT TREAT DATA VACCINES, DIAGNOSTICS MEDICINES GENETICS ANALYTICS ROBOTICS & & SENSORS AUTOMATION INTERNAL CAPABILITIES COMPLEMENTED WITH EXTERNAL PARTNERSHIPS
Slide 10: Experienced Management Team
EXPERIENCED MANAGEMENT TEAM It is our vision to have the products, services — and people — most valued by animal health customers around the world. We are proud to be led by some of the most passionate, experienced experts in the industry. JUAN RAMÓN ALAIX Chief Executive Officer HEIDI CHEN Executiv
Slide 11: Our Culture
OUR CULTURE OUR CORE BELIEFS FORM THE FOUNDATION OF OUR CULTURE AWARD-WINNING WORKPLACE
Slide 12: Accelerating Growth Together
ACCELERATING GROWTH TOGETHER
Slide 13: Next Steps
NEXT STEPS Today -Announcement • Definitive agreement signed • Each company continues to do business as usual • Important elements remain the same: your current work, compensation & benefits continue Integration Planning • Details about future integrated company begin to be determined Close – Before
Slide 14: On Your Mind
ON YOUR MIND Future Compensation, Business Benefits, Employment Structure & Policies With Zoetis Leadership
Slide 15: Questions?
QUESTIONS?
Slide 16: www.zoetis.com
www.zoetis.com zoetis.com